<< EHR Association submits responses on two regulations that implement healthcare IT incentive provisions of ARRA | MIT biochemist joins Thomson Reuters’ annual ‘Top 12’ list >>

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Published on March 16, 2010 at 5:04 AM · No Comments

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that would improve median overall survival over IFL (bolus 5-fluorouracil, generics/leucovorin, generics/irinotecan) plus bevacizumab (Roche/Genentech/Chugai's Avastin), would earn a 60 percent patient share in stage IV colorectal cancer, according to surveyed U.S. oncologists. In Europe, such an agent would earn a 50 percent patient share, according to surveyed European oncologists.

Continued on Next page >>

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancerCircadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegeni...
Combination of lunasin and oxaliplatin prevents colon cancer from metastasisA University of Illinois study reports a promising new weapon in treating metastatic colon cancer, p...
Prophylactic PEG placement prior to HNC therapy associated with high rate of non useImpairment of oral intake occurs in the majority of patients with head and neck cancer (HNC) receivi...
ACE-041 drug may provide new option to treat cancerResearchers have found that a newly developed drug, which is aimed at a particular receptor involved...
New method found for the treatment of pancreatic cancerFor the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, i...
3-drug chemotherapy combo increases organ preservation in patients with larynx cancerPatients with larynx cancer who received a three-drug combination of docetaxel, cisplatin and 5-fluo...
Cervical cancer vaccine tipped for nine year oldsHealth experts in the UK are considering vaccinating young girls of primary school age against the h...
FDA shields drug companies from lawsuitsLast month, the FDA revealed its latest protective policy for drug companies in a statement that sai...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.